Last reviewed · How we verify

NCT06096558

The Effects of Melatonin on Cardiovascular and Bone Metabolism Markers in Peritoneal Dialysis Patients

Status unknown NA Last updated 23 October 2023
What this trial tests

NA trial testing Melatonin in Peritoneal Dialysis in 46 participants. Status unknown.

Timeline
20 October 2023
Primary endpoint
20 January 2024
1 May 2024

Quick facts

Lead sponsorNational Nutrition and Food Technology Institute
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment46
Start date20 October 2023
Primary completion20 January 2024
Estimated completion1 May 2024

Drugs / interventions tested

Conditions studied

Sponsor

National Nutrition and Food Technology Institute

Who can join

Adults 18 to 75, any sex, with Peritoneal Dialysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this double-blind randomized clinical trial is to determine the effects of Melatonin on cardiovascular disease risk factors, bone metabolism markers, serum concentrations of advanced glycated end products and quality of life in peritoneal dialysis patients. Forty patients from peritoneal dialysis centers will randomly assign to either Melatonin or placebo group. The patients in Melatonin group will receive 5 mg Melatonin (as 1 tablet) daily for 10 weeks, while the placebo group will receive identical placebo. At the baseline and the end of the study,7 ml blood will be collected from each patient after a 12-14-hours fasting and Serum concentrations of malondialdehyde; high sensitivity c-reactive protein; Soluble intercellular adhesion molecule-1; glucose; pentosidine; carboxy-methyl lysine; Procollagen 1 Intact N-Terminal Propeptide; Tartrate-resistant acid phosphatase 5b; osteoprotegerin; Receptor activator of nuclear factor kappa-Β ligand; Intact parathyroid hormone; triglyceride; total cholesterol; High-density lipoprotein cholesterol; low-density lipoprotein cholesterol; lipoprotein-a; albumin; calcium; phosphorous; and also systolic blood pressure; diastolic blood pressure and questionnaires including quality of life; quality of sleep and depression will be assessed.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effects of melatonin on advanced glycation end products, inflammation, and oxidative stress in peritoneal dialysis patients: a randomized controlled trial.
    Movahedian M, Tabibi H, Atabak S, Hedayati M, et al · · 2025 · PMID 41125682 · DOI 10.1038/s41598-025-20792-2

Verify or expand the search:

Other trials of Melatonin

Trials testing the same drug.

Other recruiting trials for Peritoneal Dialysis

Currently open trials in the same condition.

Other National Nutrition and Food Technology Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06096558.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing